
Dupixent Shows Positive Results for Children Under 12 with Eosinophilic Esophagitis in Phase 3 Trial
Dupilumab (Dupixent) is the first medicine to improve signs of eosinophilic esophagitis and support weight gain in children ages 1 to 11, for whom there are no currently approved treatments.





























